| 5.81 Delayed Data As of Aug 22 |  -0.12 / -2.02%Today’s Change | 4.82 Today|||52-Week Range 14.00 | -26.18% Year-to-Date |
| CymaBay Therapeutics, Inc. (CBAY) Q2 2019 Earnings Call Transcript Aug 09 / MotleyFool.com - Paid Partner Content |
| Previous close | 5.93 |
| Today’s open | 5.95 |
| Day’s range | 5.80 - 5.98 |
| Volume | 246,352 |
| Average volume (3 months) | 1,109,910 |
| Market cap | $399.8M |
| Earnings growth (last year) | -58.86% |
| Earnings growth (this year) | -17.24% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -100.00% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 2.03 |
| Today’s change | Today’s % change | |
|---|---|---|
| DITAMCON Distributing C... | 0.00 | 0.00% |
| NUSNU Skin Enterprises ... | +0.36 | +0.89% |
| HLFHerbalife Nutrition ... | +0.79 | +2.26% |
| CAHCardinal Health Inc | +0.19 | +0.44% |
| Next reporting date | November 11, 2019 |
| EPS forecast (this quarter) | -$0.36 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$72.5M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Sujal Shah |
Chief Scientific Officer & Senior Vice President Charles A. McWherter |
Corporate headquarters Newark, California |
